|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-12-24
|
|
pubmed:abstractText |
Inorganic/organic hybrid nanoparticles are potentially useful in biomedicine, but to avoid non-specific background fluorescence and long-term toxicity, they need to be cleared from the body within a reasonable timescale. Previously, we have shown that rigid spherical nanoparticles such as quantum dots can be cleared by the kidneys if they have a hydrodynamic diameter of approximately 5.5 nm and a zwitterionic surface charge. Here, we show that quantum dots functionalized with high-affinity small-molecule ligands that target tumours can also be cleared by the kidneys if their hydrodynamic diameter is less than this value, which sets an upper limit of 5-10 ligands per quantum dot for renal clearance. Animal models of prostate cancer and melanoma show receptor-specific imaging and renal clearance within 4 h post-injection. This study suggests a set of design rules for the clinical translation of targeted nanoparticles that can be eliminated through the kidneys.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-12815134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-14520401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-14704706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-14741566,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-15258594,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-15681376,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-15928695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-16244656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-16285907,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-16608262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-16900127,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-16900224,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-17009138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-17263568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-17891134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-17983223,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18157119,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18495291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18566815,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18654343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18654426,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18711192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18758474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-18849076,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-19289434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-19422261,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-19506254,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-2388874,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-2952066,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19893516-3981257
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1748-3395
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
42-7
|
|
pubmed:dateRevised |
2011-7-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19893516-Animals,
pubmed-meshheading:19893516-Antigens, Surface,
pubmed-meshheading:19893516-Cadmium Compounds,
pubmed-meshheading:19893516-Cell Line, Tumor,
pubmed-meshheading:19893516-Diagnostic Imaging,
pubmed-meshheading:19893516-Fluorescence,
pubmed-meshheading:19893516-Glutamate Carboxypeptidase II,
pubmed-meshheading:19893516-Humans,
pubmed-meshheading:19893516-Integrin alphaV,
pubmed-meshheading:19893516-Integrin beta3,
pubmed-meshheading:19893516-Male,
pubmed-meshheading:19893516-Melanoma,
pubmed-meshheading:19893516-Mice,
pubmed-meshheading:19893516-Prostatic Neoplasms,
pubmed-meshheading:19893516-Quantum Dots,
pubmed-meshheading:19893516-Selenium Compounds,
pubmed-meshheading:19893516-Tissue Distribution
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Design considerations for tumour-targeted nanoparticles.
|
|
pubmed:affiliation |
Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
